Ubs Oconnor LLC Syndax Pharmaceuticals Inc Call Options Transaction History

Ubs Oconnor LLC

  • $1.46 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$17.93 - $24.81 $896,500 - $1.24 Million
50,000 New
50,000 $962,000
Q1 2024

May 15, 2024
BUY
$19.71 - $24.57 $47,304 - $58,968
2,400 Added 3.2%
77,400 $1.84 Million
Q4 2023

Feb 14, 2024
SELL
$11.39 - $21.67 $56,950 - $108,350
-5,000 Reduced 6.25%
75,000 $1.62 Million
Q3 2023

Nov 14, 2023
BUY
$14.52 - $21.77 $1.16 Million - $1.74 Million
80,000 New
80,000 $1.16 Million

Others Institutions Holding SNDX

# of Institutions
227
Shares Held
88.3M
Call Options Held
1.01M
Put Options Held
692K
View Full List

About Syndax Pharmaceuticals Inc

SNDX Quotes by TradingView
  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $902M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email